SCHEMBL6233072

SCHEMBL6233072

CCOC(=O)CC1=NS(=O)(=O)c2cc(I)ccc2N1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RECQL P46063 1/20 0.40
LMNA P02545 6/20 0.40
ALDH1A1 P00352 5/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
THRB P10828 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
TSHR P16473 1/20 0.40
ABCC8 Q09428 1/20 0.40
KCNJ11 Q14654 1/20 0.40
MEN1 O00255 1/20 0.40
USP2 O75604 1/20 0.40
KMT2A Q03164 1/20 0.40
TP53 P04637 2/20 0.39
NPC1 O15118 1/20 0.38
GABRA1 P14867 1/20 0.36
GABRG2 P18507 1/20 0.36
GABRB3 P28472 1/20 0.36
GABRA5 P31644 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5098238 0.89 MEN1 (0.41) RECQLLMNAALDH1A1SMN1; SMN2THRB
SCHEMBL5097715 0.87 KMT2A (0.42) RECQLLMNAALDH1A1SMN1; SMN2THRB
SCHEMBL5097658 0.85 ALDH1A1 (0.54) RECQLLMNAALDH1A1SMN1; SMN2THRB
SCHEMBL7073510 0.81 TP53 (0.39) RECQLLMNAALDH1A1SMN1; SMN2THRB
SCHEMBL6689528 0.80 MEN1 (0.39) RECQLLMNAALDH1A1SMN1; SMN2THRB
SCHEMBL6687431 0.78 TP53 (0.39) RECQLLMNAALDH1A1SMN1; SMN2CYP1A2
SCHEMBL6686746 0.78 MAPT (0.41) LMNAALDH1A1SMN1; SMN2THRBCYP1A2
SCHEMBL27649383 0.75 CHEK1 (0.37) LMNAALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL393138 0.74 ALDH1A1 (0.39) RECQLLMNAALDH1A1SMN1; SMN2THRB
SCHEMBL14338091 0.74 ALDH1A1 (0.47) RECQLLMNAALDH1A1SMN1; SMN2THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040147739-A1 Novel anti-infectives SMITHKLINE BEECHAM CORPORATION 2004-07-29 US claimed
EP-1401443-A4 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORP (US) 2005-10-26 EP disclosed
US-20040147739-A1 Novel anti-infectives SMITHKLINE BEECHAM CORPORATION 2004-07-29 US disclosed
WO-2004052312-A2 ANTI-INFECTIVES SMITHKLINE BEECHAM CORPORATION (US) 2004-06-24 WO disclosed
WO-2004052313-A2 ANTI-INFECTIVES SMITHKLINE BEECHAM CORPORATION (US) 2004-06-24 WO disclosed
EP-1401443-A1 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORPORATION (US) 2004-03-31 EP disclosed
WO-2002098424-A1 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORPORATION (US) 2002-12-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147739-A1 Novel anti-infectives RPL5, RPL7, RPL35 RECQL 1667/4885LMNA 4806/4885ALDH1A1 1494/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.